Clinical Trial Update: Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating local consolidative therapy plus brigatinib in patients with stage IV or recurrent ALK-rearranged non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Brigatinib (brigatinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Advanced Lung Carcinoma, ALK Gene Rearrangement | Phase 1 | Status: ACTIVE_NOT_RECRUITING